{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-006916","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.429517+00:00","generated_at":"2026-05-30T05:03:14.066397+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"VolitionRx appoints Timothy Still as Chairman, effective November 6, 2024","bullets":["Timothy Still appointed non-executive Chairman and director of VolitionRx; board expanded to 8 members.","Still has 35+ years in diagnostics, most recently President/CEO of Sense Biodetection (merged with Sherlock).","Compensation includes $30K/quarter retainer, 400K time-vested RSUs, and 1M performance-based RSUs tied to $2.50/$5.00 stock price targets.","Annual RSU grant of 300K shares contingent on corporate goals, subject to share availability under incentive plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-006916","json":"https://secwatch.observer/filing/0001477932-24-006916.json","markdown":"https://secwatch.observer/filing/0001477932-24-006916.md","text":"https://secwatch.observer/filing/0001477932-24-006916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793224006916/0001477932-24-006916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793224006916/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:03:14.066397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}